Adoptive B cell therapy for chronic viral infection

Front Immunol. 2022 Jul 26:13:908707. doi: 10.3389/fimmu.2022.908707. eCollection 2022.

Abstract

T cell-based therapies have been widely explored for the treatment of cancer and chronic infection, but B cell-based therapies have remained largely unexplored. To study the effect of B cell therapy, we adoptively transferred virus-specific B cells into mice that were chronically infected with lymphocytic choriomeningitis virus (LCMV). Adoptive transfer of virus-specific B cells resulted in increase in antibody titers and reduction of viral loads. Importantly, the efficacy of B cell therapy was partly dependent on antibody effector functions, and was improved by co-transferring virus-specific CD4 T cells. These findings provide a proof-of-concept that adoptive B cell therapy can be effective for the treatment of chronic infections, but provision of virus-specific CD4 T cells may be critical for optimal virus neutralization.

Keywords: B cells; adoptive cell therapy; chronic viral infection; lymphocytic choriomeningitis virus (LCMV); virus.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy
  • Immunotherapy, Adoptive
  • Lymphocytic Choriomeningitis* / therapy
  • Lymphocytic choriomeningitis virus
  • Mice
  • Mice, Inbred C57BL